Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2021-11-22 Regulatory Filings
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Expansion of BIOCERA-VET portfolio
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new partnership and product line expansion for TheraVet. It details business development, distribution agreements, and research collaborations. Since it does not fit into specific financial reporting categories like 10-K, ER, or IR, and is not a report publication announcement, it falls under the general regulatory/corporate announcement category.
2021-11-22 English
Elargissement de la gamme BIOCERA-VET
Regulatory Filings Classification · 95% confidence The document is a press release from TheraVet announcing a new strategic partnership and distribution agreement with INNOTERE to expand its product portfolio. It details the nature of the collaboration (distribution and R&D) and the specific products involved. It does not fit into financial reporting categories like 10-K or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and partnerships, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for corporate news.
2021-11-22 French
TheraVet breidt zijn BIOCERA-VET® -productlijn fors uit dankzij grote distributie- en onderzoeksovereenkomsten
Regulatory Filings Classification · 95% confidence The document is a press release dated November 22, 2021, announcing significant business developments: expansion of the BIOCERA-VET® product line through major distribution and research agreements concerning bone substitutes for veterinary use. This type of announcement, detailing strategic partnerships, product line expansions, and R&D collaborations, is characteristic of a general corporate announcement or news release, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a corporate announcement detailing strategic business updates, it fits best under the general 'Regulatory Filings' (RNS) category as a catch-all for significant, non-standardized corporate news, or potentially 'Capital/Financing Update' (CAP) if the agreements involved significant capital structure changes, but the focus here is on product/distribution strategy. Given the options, RNS is the most appropriate fallback for a detailed press release about strategic business expansion that doesn't fit a more specific financial or governance code.
2021-11-22 Dutch
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is a press release dated November 22, 2021, announcing significant business developments: expanding the product line through distribution and research agreements related to veterinary bone substitutes. This type of announcement, detailing strategic partnerships, product line expansions, and R&D collaborations, is characteristic of a general corporate update or news release, rather than a formal regulatory filing like a 10-K, IR, or ER. Since it is a strategic business announcement and not a specific financial report, management change, or shareholder vote result, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the agreements involved significant capital structuring, but the focus here is on product/business expansion. Given the options, RNS serves as the best general regulatory/corporate announcement fallback for non-standard reports. The document length (4400 chars) is substantial enough to be the primary announcement itself, not just a brief notice of publication (RPA).
2021-11-22 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated November 22, 2021, announcing significant business developments for TheraVet, specifically expanding its product line through new distribution and research agreements related to veterinary bone substitutes. It details strategic partnerships, product additions (cements, granules, 3D bio-printed parts), and R&D collaborations. This type of announcement, focusing on strategic business updates, partnerships, and product pipeline expansion, is characteristic of a general corporate announcement or press release. Since it is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a specific financial report (IR, AR), and it is not explicitly about management changes (MANG) or director dealings (DIRS), the most appropriate classification is Regulatory Filings (RNS) as a general corporate announcement that doesn't fit a more specific category, or potentially a Capital/Financing Update (CAP) if the deals involved immediate funding, but the focus here is on product/distribution expansion. Given the nature of the announcement (strategic business expansion via distribution/R&D deals), RNS serves as the best general regulatory/corporate announcement fallback. The length (5126 chars) is substantial enough to be the primary document, not just an RPA.
2021-11-22 French
TheraVet announces positive safety and efficacy results for BIOCERA-VET® in canine osteosarcoma
Regulatory Filings Classification · 95% confidence The document is a press release issued by TheraVet announcing the positive safety and efficacy results of a clinical study for their product, BIOCERA-VET. It does not fit into financial reporting categories like 10-K or IR, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding company operations and product development, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2021-11-15 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.